Studies Investigating Predictive Ability of Pretransplant PET Imaging
| Results | ||||
| Study | Patient population | PET acquisition | PET+ | PET− |
| Schot, 2006 (46) | 39 patients (11 HL, 28 NHL) | Before second-line chemotherapy, 2 cycles into treatment, and before ASCT | 2-y PFS: 27% (PET-2), 18% (PET-3) | 2-y PFS: 71% (PET-2), 60% (PET-3) |
| Svoboda, 2006 (80) | 50 patients (19 HL, 31 NHL) | After 2 cycles of salvage chemotherapy and before ASCT | Median PFS: 5 mo | Median PFS: 19 mo |
| Filmont, 2007 (47) | 60 patients (10 HL, 50 NHL) | After consolidative chemotherapy and before ASCT | 1-y EFS: 43% (pre-ASCT), 25% (post-ASCT) | 1-y EFS: 80% (pre-ASCT), 81% (post-ASCT) |
| Jabbour, 2007 (81) | 211 HL patients | After high-dose chemotherapy and before ASCT | 3-y PFS: 23%; 3-y OS: 58% | 3-y PFS: 69%; 3-y OS: 87% |
| Crocchiolo, 2008 (82) | 53 patients (14 HL, 39 NHL) | Before ASCT | 3-y PFS: 55%; 5-y OS: 55% | 3-y PFS: 79%; 5-y OS: 90% |
| Dickinson, 2010 (83) | 39 DLBCL patients | Before ASCT | 3-y PFS: 35% | 3-y PFS: 81% |
| Moskowitz, 2010 (84) | 153 HL patients | After ICE-based salvage chemotherapy and high-dose chemotherapy, and before/after ASCT | 5-y EFS: 31% | 5-y EFS: 75% |
| Qiao, 2010 (48) | 31 NHL patients | Before/after ASCT | 1-y PFS: 28.6% (pre-ASCT), 23.1% (post-ASCT) | 1-y PFS: 88.2% (pre-ASCT), 88.9% (post-ASCT) |
| Mocikova, 2011 (85) | 76 HL patients | After salvage chemotherapy and before ASCT | 2-y PFS: 36.1%; 2-y OS: 61.4% | 2-y PFS: 72.7%; 2-y OS: 90.3% |
| Moskowitz, 2012 (86) | 97 HL patients | After salvage chemotherapy | EFS: 28.6% | EFS: > 80% |
| Cohen, 2013 (87) | 29 mantle cell lymphoma patients | Before ASCT | 2-y PFS: 64%; 2-y OS: 60% | 2-y PFS: 87%; 2-y OS: 100% |
EFS = event-free survival; OS = overall survival.